edoc

Items where Author is "Mullhaupt, B."

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Date | Item Type | Refereed
Jump to: 2014 | 2013 | 2012 | 2011 | 2009 | 2008
Number of items: 11.

2014

Frei, P. and Leucht, A. K. and Held, U. and Kofmehl, R. and Manser, C. N. and Schmitt, J. and Mertens, J. and Rau, M. and Baur, K. and Gerlach, T. and Negro, F. and Heim, M. and Moradpour, D. and Cerny, A. and Dufour, J. F. and Mullhaupt, B. and Geier, A.. (2014) Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon-alpha and ribavirin in chronic hepatitis C virus patients. Liver international, Vol. 34, H. 4. pp. 551-557.

2013

Lange, C. M. and Bibert, S. and Dufour, J. F. and Cellerai, C. and Cerny, A. and Heim, M. H. and Kaiser, L. and Malinverni, R. and Mullhaupt, B. and Negro, F. and Semela, D. and Moradpour, D. and Kutalik, Z. and Bochud, P. Y.. (2013) Comparative genetic analyses point to HCP5 as susceptibility locus for HCV-associated hepatocellular carcinoma. Journal of hepatology, Vol. 59, H. 3. pp. 504-509.

Zeuzem, S. and Asselah, T. and Angus, P. and Zarski, J. P. and Larrey, D. and Mullhaupt, B. and Gane, E. and Schuchmann, M. and Lohse, A. W. and Pol, S. and Bronowicki, J. P. and Roberts, S. and Arasteh, K. and Zoulim, F. and Heim, M. and Stern, J. O. and Nehmiz, G. and Kukolj, G. and Bocher, W. O. and Mensa, F. J.. (2013) Faldaprevir (BI 201335), BI 207127 and ribavirin oral therapy for treatment-naive HCV genotype 1 : SOUND-C1 final results. Antiviral therapy, Vol. 18, H. 8. pp. 1015-1019.

Lange, C. M. and Miki, D. and Ochi, H. and Nischalke, H. D. and Bojunga, J. and Bibert, S. and Morikawa, K. and Gouttenoire, J. and Cerny, A. and Dufour, J. F. and Gorgievski-Hrisoho, M. and Heim, M. H. and Malinverni, R. and Mullhaupt, B. and Negro, F. and Semela, D. and Kutalik, Z. and Muller, T. and Spengler, U. and Berg, T. and Chayama, K. and Moradpour, D. and Bochud, P. Y.. (2013) Genetic analyses reveal a role for vitamin D insufficiency in HCV-associated hepatocellular carcinoma development. PLoS ONE, Vol. 8, H. 5 , e64053.

2012

Kuske, L. and Mensen, A. and Mullhaupt, B. and Negro, F. and Semela, D. and Moradpour, D. and Male, P. J. and Heim, M. H. and Malinverni, R. and Cerny, A. and Dufour, J. F.. (2012) Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma. Swiss medical weekly, Vol. 142 , w13651.

Patin, E. and Kutalik, Z. and Guergnon, J. and Bibert, S. and Nalpas, B. and Jouanguy, E. and Munteanu, M. and Bousquet, L. and Argiro, L. and Halfon, P. and Boland, A. and Mullhaupt, B. and Semela, D. and Dufour, J. F. and Heim, M. H. and Moradpour, D. and Cerny, A. and Malinverni, R. and Hirsch, H. and Martinetti, G. and Suppiah, V. and Stewart, G. and Booth, D. R. and George, J. and Casanova, J. L. and Brechot, C. and Rice, C. M. and Talal, A. H. and Jacobson, I. M. and Bourliere, M. and Theodorou, I. and Poynard, T. and Negro, F. and Pol, S. and Bochud, P. Y. and Abel, L.. (2012) Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. Gastroenterology, Vol. 143, H. 5 , S. 1244-1252.e12.

Bochud, P. Y. and Bibert, S. and Kutalik, Z. and Patin, E. and Guergnon, J. and Nalpas, B. and Goossens, N. and Kuske, L. and Mullhaupt, B. and Gerlach, T. and Heim, M. H. and Moradpour, D. and Cerny, A. and Malinverni, R. and Regenass, S. and Dollenmaier, G. and Hirsch, H. and Martinetti, G. and Gorgiewski, M. and Bourliere, M. and Poynard, T. and Theodorou, I. and Abel, L. and Pol, S. and Dufour, J. F. and Negro, F.. (2012) IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology, Vol. 55, H. 2. pp. 384-394.

Lange, C. M. and Kutalik, Z. and Morikawa, K. and Bibert, S. and Cerny, A. and Dollenmaier, G. and Dufour, J. F. and Gerlach, T. J. and Heim, M. H. and Malinverni, R. and Mullhaupt, B. and Negro, F. and Moradpour, D. and Bochud, P. Y.. (2012) Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy. Hepatology, Vol. 55, H. 4. pp. 1038-1047.

2011

Zeuzem, S. and Asselah, T. and Angus, P. and Zarski, J. P. and Larrey, D. and Mullhaupt, B. and Gane, E. and Schuchmann, M. and Lohse, A. and Pol, S. and Bronowicki, J. P. and Roberts, S. and Arasteh, K. and Zoulim, F. and Heim, M. and Stern, J. O. and Kukolj, G. and Nehmiz, G. and Haefner, C. and Boecher, W. O.. (2011) Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology, Vol. 141, H. 6. pp. 2047-2055.

2009

Riener, M. O. and Stenner, F. and Liewen, H. and Soll, C. and Breitenstein, S. and Pestalozzi, B. C. and Samaras, P. and Probst-Hensch N., and Hellerbrand, C. and Mullhaupt, B. and Clavien, P. A. and Bahra, M. and Neuhaus, P. and Wild, P. and Fritzsche, F. and Moch, H. and Jochum, W. and Kristiansen, G.. (2009) Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology : official journal of the American Association for the Study of Liver Diseases, Vol. 49, No. 5. pp. 1602-1609.

2008

Helbling, B. and Overbeck, K. and Gonvers, J.-J. and Malinverni, R. and Dufour, J.-F. and Borovicka, J. and Heim, M. and Cerny, A. and Negro, F. and Bucher, S. and Rickenbach, M. and Renner, E. L. and Mullhaupt, B.. (2008) Host- rather than virus-related factors reduce health-related quality of life in hepatitis C virus infection. Gut, Vol. 57, H. 11. pp. 1597-1603.

This list was generated on Thu Apr 18 19:33:31 2024 CEST.